Oncogenic PIK3CA recruits myeloid‐derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5‐lipoxygenase‐dependent arachidonic acid pathway
Clinical and Translational Medicine · 2023-11 · 13 (11)
DOI: 10.1002/ctm2.1483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 15.11.2023. Verfasst von Xingchen Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin's C…. Hauptthemen laut MEDLINE: Breast Neoplasms, Myeloid-Derived Suppressor Cells. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Science Foundation of Tianjin, National Science and Technology Support Program of China.
Abstract (Originalsprache)
Background
Oncogenic PIK3CA mutations (PIK3CA mut ) frequently occur in a higher proportion in luminal breast cancer (LBC), especially in refractory advanced cases, and are associated with changes in tumour cellular metabolism. Nevertheless, its effect on the progression of the immune microenvironment (TIME) within tumours and vital molecular events remains veiled.
Methods
Multiplex immunohistochemistry (mIHC) and single‐cell mass cytometry (CyTOF) was used to describe the landscape of TIME in PIK3CA mut LBC. The PIK3CA mutant cell lines were established using CRISPER/Cas9 system. The gene expression levels, protein secretion and activity of signaling pathways were measured by real‐time RT‐PCR, ELISA, immunofluorescence staining or western blotting. GSEA analysis, transwell chemotaxis assay, live cell imaging, flow cytometry metabolite analysis targeting arachidonic acid, Dual‐luciferase reporter assay, and Chromatin immunoprecipitation assay were used to investigate the underlying function and mechanism of the PI3K/5‐LOX/LTB4 axis.
Results
PIK3CA mut LBC cells can induce an immunosuppressive TIME by recruiting myeloid‐derived suppressor cells (MDSCs) and excluding cytotoxic T cells via the arachidonic acid (AA) metabolism pathway. Mechanistically, PIK3CA mut activates the transcription of 5‐lipoxygenase (5‐LOX) in a STAT3‐dependent manner, which in turn directly results in high LTB4 production, binding to BLT2 on MDSCs and promoting their infiltration. Since a suppressive TIME is a critical barrier for the success of cancer immunotherapy, the strategies that can convert “cold” tumours into “hot” tumours were compared. Targeted therapy against the PI3K/5‐LOX/LTB4 axis synergizing with immune checkpoint blockade (ICB) therapy achieved dramatic shrinkage in vivo.
Conclusions
The results emphasize that PIK3CA mut can induce immune evasion by recruiting MDSCs through the 5‐LOX‐dependent AA pathway, and combination targeted therapy with ICB may provide a promising treatment option for refractory advanced LBC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.
- Department of Thyroid and Neck, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
- Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
ORCID-Profile: Jinpu Yu
Förderung
- National Natural Science Foundation of China
- National Science Foundation of Tianjin
- National Science and Technology Support Program of China
- Tianjin Health Research Project
- Tianjin Research Innovation Project for Postgraduate Students
Zitieren
APA
Li, X., Chen, G., Wang, F., Guo, X., Zhang, R., Liu, P., Dong, L., Yu, W., Wang, H., Wang, H., & Yu, J. (2023). Oncogenic PIK3CA recruits myeloid‐derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5‐lipoxygenase‐dependent arachidonic acid pathway. Clinical and Translational Medicine, 13(11). https://doi.org/10.1002/ctm2.1483
Vancouver
Li X, Chen G, Wang F, Guo X, Zhang R, Liu P, et al. Oncogenic PIK3CA recruits myeloid‐derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5‐lipoxygenase‐dependent arachidonic acid pathway. Clinical and Translational Medicine. 2023;13(11). doi:10.1002/ctm2.1483
BibTeX
@article{Li2023,
author = {Li, Xingchen and Chen, Guidong and Wang, Fanchen and Guo, Xiaojing and Zhang, Rui and Liu, Pengpeng and Dong, Li and Yu, Wenwen and Wang, Huan and Wang, Hailong and Yu, Jinpu},
title = {Oncogenic PIK3CA recruits myeloid‐derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5‐lipoxygenase‐dependent arachidonic acid pathway},
journal = {Clinical and Translational Medicine},
year = {2023},
volume = {13},
number = {11},
doi = {10.1002/ctm2.1483}
}
EUVIMED